Effect of 16, 16 dimethyl prostaglandin E2 on aspirin-induced permeability changes in the pancreatic duct.
Perfusion of the pancreatic duct with acidified aspirin in cats increased the permeability of the duct to HCO3-. Intravenous administration of the synthetic prostaglandin analog 16,16 dimethyl prostaglandin E2 (PGE2) prevented this permeability change. The effect was dose-related and at the highest dose (50 microgram/kg/hour) was essentially complete. The beneficial effect of the PGE2 was apparent even when it was given after the duct had been exposed to aspirin. PGE2 had no effect on pancreatic water or electrolyte secretion in the unstimulated nonsecreting gland. No histologic changes in the pancreatic ducts were seen after exposure to aspirin, PGE2 or both. The effectiveness of PGE2 in restoring membrane permeability towards normal suggests the possibility of its therapeutic role in pancreatitis.
D015064:16,16-Dimethylprostaglandin E2 / Q000494:pharmacology*; D000818:Animals; D000838:Anions; D001241:Aspirin / Q000037:antagonists & inhibitors*; D001639:Bicarbonates; D002415:Cats; D004305:Dose-Response Relationship, Drug; D010183:Pancreatic Ducts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010477:Perfusion; D010539:Permeability; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*
D000838:Anions; D001639:Bicarbonates; D011459:Prostaglandins E, Synthetic; D015064:16,16-Dimethylprostaglandin E2; D001241:Aspirin